GSA Capital Partners LLP Sells 78,250 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

GSA Capital Partners LLP reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 21.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 285,588 shares of the biotechnology company’s stock after selling 78,250 shares during the period. GSA Capital Partners LLP’s holdings in BioCryst Pharmaceuticals were worth $2,170,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. CWM LLC grew its position in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,322 shares during the last quarter. nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $63,000. Finally, Seven Eight Capital LP bought a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $57,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 5.3 %

BioCryst Pharmaceuticals stock opened at $8.19 on Tuesday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The stock has a market cap of $1.70 billion, a P/E ratio of -13.43 and a beta of 1.89. The company’s 50-day moving average price is $7.75 and its two-hundred day moving average price is $7.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.19) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BCRX. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, JMP Securities upped their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.